A Phase 4 interventional study of Bacterial Lysate and Placebo in Respiratory Tract Infections (RTI), sponsored by Campus Bio-Medico University. Recruiting at 1 site in Italy. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2025-03-18.
Sponsored by Campus Bio-Medico University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Respiratory Tract Infections with a site in Italy — 11 open to participants now, 13 under way, 2 of them phase 3. Respiratory Tract Infections · Italy.
Among the 34 studies in Respiratory Tract Infections with a site in Italy, this one is the 9th largest by planned enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2025, is one of 5 in phase 4, reaches primary completion later than 3 of the 12 other live ones, and was the 27th registered.
753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.
Browse Respiratory Tract Infections studies →11 of the 34 studies in Respiratory Tract Infections with a site in Italy are open now. Recruiting first, the newest first:
University Hospital, Grenoble · Sites in Italy, United States, France and 2 more countries
Ages 60+
Azienda Ospedaliero-Universitaria Careggi · Sites in Italy
Ages 18–90
Laboratorio Farmaceutico SIT srl · Sites in Italy, North Macedonia
Ages 18–99
Cardarelli Hospital · Sites in Italy
Ages 18+
AstraZeneca · Sites in Italy, United States, Argentina and 36 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 73 Respiratory Tract Infections studies recruiting now, 33 (45%) set no upper age limit and 32 (44%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 75 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 9 · Phase 4 5
First in 2005; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 360 is above the median of 200 across 542 interventional studies indexed under Respiratory Tract Infections.
Median enrollment 252 across the 23 interventional studies, 700 across the 10 observational. Of the 20 that completed or were terminated, 3 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 34 have an industry lead sponsor. The 10 most frequent:
Campus Bio-Medico University is the lead sponsor of 84 studies on the registry; 11 are open to participants now.
Campus Bio-Medico University has 1 study filed under Respiratory Tract Infections — fewer than ten, so there is no comparison to draw.
2 of the studies in Respiratory Tract Infections with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06736288Laboratorio Farmaceutico SIT srlPost Authorization Efficacy and Safety Study (PAES) to Confirm and Collect More Clinical Data of Buccalin® Tablets In the Prophylaxis of Recurrent Lower Respiratory Tract Infections (RLRTIs). | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 34 studies in Respiratory Tract Infections with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
People living in NH are at higher risk of respiratory infections compared to their counterpart living in the community. Products obtained from dead bacteria ("bacterial lysate") can be used to boost immune system and may reduce the risk of respiratory infections. Very little information is available on the effect of these substances in older people. This study will evaluate the efficacy of a bacterial lysate in reducing the incidence of lower respiratory tract infections in older people living in nursing homes. The study will include a treatment arm, in which participants will received the lysate, and a control arm in which participants will received a matching placebo (i.e., a pill that has the same appearance of the lysate but does not contain the lysate itself).
OM 85 (lyophilized bacterial lysate) proved effective in increasing the immune response against bacteria in animal models. Furthermore, its use was shown to be associated with lower incidence of RTIs in children and at risk adults. However, there is a paucity of information about OM 85 efficacy in the elderly, i.e., in a population which, due to immunosenescence and multimorbidity, might have a distinctive response to this immunostimulating strategy. Indeed, the only study properly designed for a geriatric population is a randomized controlled trial on 290 people over-65 with chronic bronchitis and frequent exacerbations; here, a significant decrease in the incidence of acute bronchitis was observed in the OM 85 group over 6 months (Orcel B et al. Eur Respir J, 1994, 7, 446-452). However, this population seems poorly representative of the average older population at risk of RTI. Indeed, chronic diseases like congestive heart failure and chronic renal failure qualified as exclusion criteria. Furthermore, a history of at least 4 episodes of acute bronchitis treated with antibiotics in the 6-month reference period of the previous year were requested for the enrollment. Thus, the study population is unlikely to reflect the profile of risk of the elderly and frail population, which is characterized by a high prevalence of chronic diseases, but not by such a high incidence of respiratory infections. Indeed, even in severe COPD the frequency of exacerbations rarely exceeds 2 yearly and is rapidly declining (Andreas et al. Respiratory Research (2019) 20:186). Geriatric patients are variably represented in other studies which proved the efficacy of OM 85 in adult populations with COPD or chronic bronchitis. Twelve studies met the quality criteria to be eligible for a recently published meta-analysis (Huang Y, Pei Y, Qian Y, Yao Z, Chen C, Du J, Shi M, and Zhou T, 2022. A meta-analysis on the efficacy and safety of bacterial lysates in chronic obstructive pulmonary disease. Front. Med. 9:877124. doi: 10.3389/fmed.2022.877124). However, elderly patients and especially those over 75, the most vulnerable to respiratory infections, were a minority of probands. Furthermore, the selection criteria pointed at COPD as the main disease in the vast majority of the studies. IMP has never been tested in an older population with a heavy burden of multimorbility and frailty and a high risk of RTI, I e in the population most likely to benefit from it. Accordingly, this trial is expected to clarify what previous studies could not because they were not designed to study this kind of population, and only sparse and partial information could be derived by picking selected patients from the study populations. Furthermore, all our patients will receive the recommended vaccines, and this will allow test IMP in a framework free from confounding by heterogeneity in vaccine policy.
Primary objective:
To evaluate whether and to which extent OM85 compared with placebo is able to reduce respiratory tract infections (RTIs) over a 12-month period in a population of subjects aged 75 years and older, residing in nursing homes, and with a history of at least two RTIs in the 12 months prior to enrollment.
Secondary objectives:
To verify whether the rate of hospital admissions and emergency department visits due to RTI decreases from the previous year differently in the OM 85 group compared with placebo.
Evaluate the number of antibiotic prescriptions between the two groups (OM 85 and placebo) during the 12-month study period.
Describe the demographic, clinical and functional characteristics of patients with higher RTI numbers.
Evaluate the incidence of treatment-emergent adverse events (TEAEs).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bacterial lysate p.o. administered for two three-months cycles.
Drug: Bacterial Lysate
Matching placebo.
Drug: Placebo
Administration p.o. for 10 days per month for 3 months, two consecutive cycles.
Matching placebo.
Incidence of lower respiratory tract infections.
New cases of clinically-diagnosed lower respiratory tract infections
Time frame: 12 months
Rate of hospitalizations and emergency room admissions
Rate of hospitalizations and emergency room admissions due to respiratory tract infections.
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Jan 2026, 11 months after the start.
Of 29 phase 4 interventional studies under Respiratory Tract Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 51. This study's planned 11 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Tract Infections →
Campus Bio-Medico University